Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.

Kinstrie R, Karamitros D, Goardon N, Morrison H, Hamblin M, Robinson L, Clark RE, Copland M, Vyas P.

Blood Adv. 2016 Dec 14;1(3):160-169. doi: 10.1182/bloodadvances.2016000810. eCollection 2016 Dec 27.

2.

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.

Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P, Cruz M, Dunn K, Jorgensen HG, Cassels JE, Hamilton A, Crossan A, Sinclair A, Holyoake TL, Vetrie D.

Cancer Discov. 2016 Nov;6(11):1248-1257. Epub 2016 Sep 14.

3.

CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells.

Sinclair A, Park L, Shah M, Drotar M, Calaminus S, Hopcroft LE, Kinstrie R, Guitart AV, Dunn K, Abraham SA, Sansom O, Michie AM, Machesky L, Kranc KR, Graham GJ, Pellicano F, Holyoake TL.

Blood. 2016 Jul 21;128(3):371-83. doi: 10.1182/blood-2015-08-661785. Epub 2016 May 24.

4.

Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.

Irvine DA, Zhang B, Kinstrie R, Tarafdar A, Morrison H, Campbell VL, Moka HA, Ho Y, Nixon C, Manley PW, Wheadon H, Goodlad JR, Holyoake TL, Bhatia R, Copland M.

Sci Rep. 2016 May 9;6:25476. doi: 10.1038/srep25476.

5.

Novel drug therapies in myeloid leukemia.

Horne GA, Kinstrie R, Copland M.

Pharm Pat Anal. 2015;4(3):187-205. doi: 10.4155/ppa.15.3. Review.

6.

Targeting chronic myeloid leukemia stem cells.

Kinstrie R, Copland M.

Curr Hematol Malig Rep. 2013 Mar;8(1):14-21. doi: 10.1007/s11899-012-0148-8. Review.

PMID:
23264204
7.

Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.

Eyre T, Schwab CJ, Kinstrie R, McGuire AK, Strefford J, Peniket A, Mead A, Littlewood T, Holyoake TL, Copland M, Moorman AV, Harrison CJ, Vyas P.

Blood. 2012 Nov 22;120(22):4441-3. doi: 10.1182/blood-2012-09-456517. No abstract available.

8.

Universal expression and dual function of the atypical chemokine receptor D6 on innate-like B cells in mice.

Hansell CA, Schiering C, Kinstrie R, Ford L, Bordon Y, McInnes IB, Goodyear CS, Nibbs RJ.

Blood. 2011 May 19;117(20):5413-24. doi: 10.1182/blood-2010-11-317115. Epub 2011 Mar 30.

9.

Characterization of a domain that transiently converts class 2 DYRKs into intramolecular tyrosine kinases.

Kinstrie R, Luebbering N, Miranda-Saavedra D, Sibbet G, Han J, Lochhead PA, Cleghon V.

Sci Signal. 2010 Mar 2;3(111):ra16. doi: 10.1126/scisignal.2000579.

10.

A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation.

Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V.

Mol Cell. 2006 Nov 17;24(4):627-33.

11.

dDYRK2 and Minibrain interact with the chromatin remodelling factors SNR1 and TRX.

Kinstrie R, Lochhead PA, Sibbet G, Morrice N, Cleghon V.

Biochem J. 2006 Aug 15;398(1):45-54.

12.

dDYRK2: a novel dual-specificity tyrosine-phosphorylation-regulated kinase in Drosophila.

Lochhead PA, Sibbet G, Kinstrie R, Cleghon T, Rylatt M, Morrison DK, Cleghon V.

Biochem J. 2003 Sep 1;374(Pt 2):381-91.

Supplemental Content

Loading ...
Support Center